16,699 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Bought by M&T Bank Corp

M&T Bank Corp purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 16,699 shares of the medical instruments supplier’s stock, valued at approximately $1,551,000.

Other large investors have also made changes to their positions in the company. Barclays PLC raised its stake in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the period. MML Investors Services LLC grew its holdings in LeMaitre Vascular by 2.8% during the 3rd quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock valued at $660,000 after buying an additional 191 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of LeMaitre Vascular during the third quarter valued at approximately $344,000. DF Dent & Co. Inc. lifted its holdings in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after buying an additional 53,797 shares in the last quarter. Finally, State Street Corp boosted its position in shares of LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after acquiring an additional 28,525 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $100.69 on Friday. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 55.02, a PEG ratio of 2.47 and a beta of 0.93. The firm’s 50-day moving average is $97.65 and its two-hundred day moving average is $89.54. LeMaitre Vascular, Inc. has a 1 year low of $52.88 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Analyst Ratings Changes

Several brokerages have recently issued reports on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research increased their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. JMP Securities raised their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Finally, Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.